[1] |
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109. doi: 10.1007/s00401-007-0243-4
|
[2] |
Singhal T, Narayanan TK, Jain V, et al. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas[J]. Mol Imaging Biol, 2008, 10(1):1-18.
|
[3] |
王全师. 11C-蛋氨酸PET/CT显像在脑胶质瘤中的初步应用[J].中华核医学杂志, 2005, 25(5):286-287.
|
[4] |
Van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation[J]. Curr Pharm Des, 2008, 14(31):3326-3339. doi: 10.2174/138161208786549399
|
[5] |
LảngstrÖm B, Antoni G, Gullberg P, et al. Synthesis of L- and D-[methyl-11C]methionine[J]. J Nucl Med, 1987, 28(6):1037-1040.
|
[6] |
Glaudemans AW, Enting RH, Heesters MA, et al. Value of 11C-methionine PET in imaging brain tumours and metastases[J]. Eur J Nucl Med Mol Imaging, 2013, 40(4):615-635. doi: 10.1007/s00259-012-2295-5
|
[7] |
Li DL, Xu YK, Wang QS, et al. 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas[J]. Chin Med J, 2012, 125(1):91-96.
|
[8] |
Yamane T, Sakamoto S, Senda M. Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm[J]. Eur J Nucl Med Mol Imaging, 2010, 37(4):685-690. doi: 10.1007/s00259-009-1302-y
|
[9] |
Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma[J]. J Neurosurg, 2005, 103(3):498-507. doi: 10.3171/jns.2005.103.3.0498
|
[10] |
Sadeghi N, Salmon I, Decaestecker C, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma[J]. AJNR Am J Neuroradiol, 2007, 28(3):455-461.
|
[11] |
Shinozaki N, Uchino Y, Yoshikawa K, et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography[J]. J Neurosurg, 2011, 114(6):1640-1647. doi: 10.3171/2010.11.JNS10553
|
[12] |
Galldiks N, Kracht LW, Berthold F, et al.[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors[J]. J Neurooncol, 2010, 96(2):231-239. doi: 10.1007/s11060-009-9953-x
|
[13] |
Ceyssens S, Van Laere K, De Groot T, et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence[J]. AJNR Am J Neuroradiol, 2006, 27(7):1432-1437.
|
[14] |
Yamamoto Y, Nishiyama Y, Kimura N, et al. 11C-acetate PET in the evaluation of brain glioma:comparison with 11C-methionine and 18F-FDG-PET[J]. Mol Imaging Biol, 2008, 10(5):281-287.
|
[15] |
胡晓云, 胡春洪, 方向明, 等.脑胶质瘤的11C-甲硫氨酸和11C-胆碱PET和PET-CT[J].国际放射医学核医学杂志, 2008, 32(1):20-23. doi: 10.3760/cma.j.issn.1673-4114.2008.01.006
|
[16] |
Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas[J]. Eur J Nucl Med Mol Imaging, 2008, 35(1):65-71. doi: 10.1007/s00259-007-0531-1
|
[17] |
Kim S, Chung JK, Im SH, et al. 11C-methionine PET as a prognostic marker in patients with glioma:comparison with 18F-FDG PET[J]. Eur J Nucl Med Mol Imaging, 2005, 32(1):52-59. doi: 10.1007/s00259-004-1598-6
|
[18] |
Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with[11C] methionine PET in patients with low-grade astrocytoma[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):43-52. doi: 10.1016/S0360-3016(00)00604-0
|
[19] |
Gumprecht H, Grosu AL, Souvatsoglou M, et al. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas[J]. Zentralbl Neurochir, 2007, 68(1):19-23. doi: 10.1055/s-2007-970601
|
[20] |
Okamoto S, Shiga T, Hattori N, et al. Semiquantitative analysis of C-11 methionine PET May distinguish brain tumor recurrence from radiation necrosis even in small lesions[J]. Ann Nucl Med, 2011, 25(3):213-220.
|
[21] |
Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine(FET)- and L-[methyl-11C]methionine(Met)-PET in patients with brain gliomas and metastases[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):1049-1058. doi: 10.1016/j.ijrobp.2010.07.002
|